LBRX
LB Pharmaceuticals Inc
NASDAQ NMS - GLOBAL MARKET· Pharmaceuticals· US· IPO 2025-09-11
$40.33
+1.29 (+3.30%)
last quote
Want the full multi-source brief on LBRX?
The agent pulls regulatory filings, news flow, prediction-market pricing, and macro context — then synthesizes what's not yet in the price.
Today
Open
$40.33
High
$41.40
Low
$39.15
Previous close
$39.04
Fundamentals
Market cap
$1.26B
P/E (TTM)
—
P/S (TTM)
—
P/B
1.87x
Gross margin
—
Operating margin
—
Net margin
—
Rev growth (YoY)
—
EPS growth (YoY)
—
ROE
-25.91%
52W high
$50.16
52W low
$14.32
Beta
1.77x
Industry peers
by market cap
Upcoming earnings
next 30 days
2026-11-05today
Q3 2026EPS est $-1.65
Recent SEC filings
CIK 1691082filing-language history →
Recent news
2026-10-28 → 2026-11-04
Yahoo · 6d
Guggenheim names LB Pharmaceuticals a top idea ahead of pivotal trial data
Guggenheim Securities reiterated its buy rating on LB Pharmaceuticals and named the biotechnology company a top investment idea, citing promising clinical data for its experimental schizophrenia drug LB-102 and potential expansion into mood disorders ahead of a pivotal trial readout expected in the first half of 2027.
Yahoo · 7d
LB Pharmaceuticals Eyes 2027 Phase III Data for LB-102 in Schizophrenia
LB Pharmaceuticals (NASDAQ:LBRX) outlined its clinical and commercial plans for LB-102, an investigational antipsychotic designed as a structural modification of amisulpride, during its first R&D Day in New York. The company said it expects three clinical readouts over the next three years, begi
This is the free preview
The agent layer adds regulatory-language drift detection, cross-venue prediction-market signals, macro overlays, programmable alert rules, overnight briefs, and a grounding verifier on every claim. 7-day Pro trial, no card required.
Start the trial